More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
# Beta Finch Podcast Script: Zoetis Q1 2026 Earnings
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into quarterly results to help you understand what's really happening in the market. I'm Alex.
**JORDAN:** And I'm Jordan. Before we dig in, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**ALEX:** Today we're breaking down Zoetis' Q1 2026 earnings - and wow, this was a quarter that really caught investors off guard. Jordan, what's your first take on these numbers?
**JORDAN:** Alex, this was definitely a reality check for the animal health giant. On the surface, flat organic operational revenue growth doesn't look terrible, but when you peel back the layers, there's a lot more going on here. They had about $100 million in sales that shifted from Q4 2025 into Q1 due to fiscal year alignment changes. Without that boost, they would have seen a 5% organic operational decline.
**ALEX:** That's a significant difference. And CEO Kristin Peck was pretty candid about what went wrong, wasn't she?
**JORDAN:** Absolutely. She laid out four key factors that created what she called "a convergence of interconnected dynamics." First, rising prices at veterinary clinics led to lower clinic traffic - pet owners are feeling the pinch. Second, those same pet owners are showing increased price sensitivity, especially for premium products where Zoetis leads. Third, competition intensified across key categories like dermatology and parasiticides, with competitors using aggressive pricing. And fourth - this is crucial - these competitive launches didn't expand the overall market like they have historically.
**ALEX:** That last point seems really important. Historically, when new competitors entered Zoetis markets, the pie got bigger for everyone. But not this time?
**JORDAN:** Exactly. In the past, competition actually helped grow markets - think about how the parasiticide market expanded when new players came in. But this time, with pet owners being more price-conscious and visiting clinics less frequently, new entrants are just taking share from existing players rather than bringing new customers into the market.
**ALEX:** Let's talk specific numbers. How did their key franchises perform?
**JORDAN:** The companion animal business really struggled, particularly in the U.S. where it declined 11%. Their key dermatology franchise - which includes blockbusters like Apoquel and Cytopoint - fell 11% globally to $347 million. The Simparica parasiticide franchise was down 1% to $385 million globally, but that masks an 8% decline in the U.S. And their OA Pain products, Librela and Solensia, dropped 8% combined to $140 million.
**ALEX:** But it wasn't all bad news, right? I noticed livestock performed well.
**JORDAN:** That's the silver lining here. Livestock delivered 12% organic operational growth to $720 million, with broad-based strength across cattle, poultry, and swine. Favorable producer economics and strong protein demand are driving investment in herd health. It really shows the value of Zoetis' diversified portfolio - when companion animal struggles, livestock can pick up some slack.
**ALEX:** What about guidance? I imagine they had to adjust expectations.
**JORDAN:** They definitely had to recalibrate. Full-year revenue growth guidance came down to 2-5% from what was presumably higher expectations, and adjusted net income growth is now expected at 2-6%. CFO Wetteny Joseph noted that while the fiscal year alignment was supposed to provide a 200-250 basis point tailwind, the challenging operating environment more than offset that benefit.
**ALEX:** During the Q&A, there were some pointe
This episode includes AI-generated content.
Show More
Show Less
May 7 20268 mins